Within the past ten years significant advances have been made in knowledge of the mechanisms of action as well as resistance to antitumor agents. This knowledge has in turn facilitated the design of new approaches in the minimization of limiting drug toxicities. Unfortunately, the discovery of large numbers of new drugs useful at the clinical level has been far less successful than was originally hoped. Therefore, developing newer ways of using older but effective chemotherapeutic agents will for the near future continue to be an important basic and clinical research goal. Since its inception in 1977, our lab has had as its long-term objective the improvement of the efficacy of anticancer chemotherapy by seeking both to understand the mechanisms of the toxicity to new, as well as established, antitumor drugs and to explore the rational pharmacologic intervention of these limiting toxicities. Efforts aimed at understanding the basic pathogenesis of pulmonary fibrosis as well as the prediction and prevention of pulmonary disease due to bleomycin analogs comprise the first project in the resubmission of a RESEARCH CAREER DEVELOPMENT AWARD application. Acute pulmonary changes due to administration to rats of bleomycin and related analogs will be assessed by determination of tissue, serum and bronchoalveolar lavage enzyme activities (angiotensin-converting and prolyl hydroxylase activities). These will be compared to dose and time-dependent changes in lung histopathology and collagen metabolism. The utility and efficacy of L-dehydroproline as an antifibrotic agent will be determined. Finally, the in vitro coculture of macrophages obtained by lung lavage together with lung fibroblasts will be studied to understand the interaction of these two cell types in the early pathogenesis of drug-mediated fibrosis. The second project involves development of the fetal mouse heart organ culture system as a useful tool in examining anthracycline-mediated cardiomyopathy. Drug-induced leakage of lactic dehydrogenase (LDH) and creatine phosphokinase (CPK) activities will be compared to histopathologic changes in an attempt to 1) produce a model of cardiomyopathy that will quickly and accurately permit determination of cardiac drug toxicities and 2) also permit a model for evaluation of the merit of 'cardioprotectant' agents (ICRF - 190, Vit. E. carnitine, adenosine, etc.) in blocking adverse anthracycline cardiac effects.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Modified Research Career Development Award (K04)
Project #
5K04CA001135-03
Application #
3071691
Study Section
Experimental Therapeutics Subcommittee 2 (ET)
Project Start
1985-06-01
Project End
1988-12-31
Budget Start
1986-01-01
Budget End
1986-12-31
Support Year
3
Fiscal Year
1986
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
Hospitals
DUNS #
001910777
City
Houston
State
TX
Country
United States
Zip Code
77030
Farquhar, D; Newman, R A; Zuckerman, J E et al. (1991) Doxorubicin analogues incorporating chemically reactive substituents. J Med Chem 34:561-4
Wassermann, K; Zwelling, L A; Lown, J W et al. (1990) Liblomycin-mediated DNA cleavage in human head and neck squamous carcinoma cells and purified DNA. Cancer Res 50:1732-7
Engineer, M S; Brown, N S; Ho, D H et al. (1989) A comparison of the effects of tetraplatin and cisplatin on renal function and gentamicin pharmacology in rats. Toxicology 59:151-62
Raber, M N; Newman, R A; Lu, K et al. (1989) Phase I clinical trial and pharmacokinetic evaluation of 4'-0-tetrahydropyranyladriamycin (THP-adriamycin). Cancer Chemother Pharmacol 23:311-5
Lazo, J S; Braun, I D; Labaree, D C et al. (1989) Characteristics of bleomycin-resistant phenotypes of human cell sublines and circumvention of bleomycin resistance by liblomycin. Cancer Res 49:185-90
Bull, J M; Strebel, F R; Sunderland, B A et al. (1988) o-(beta-Hydroxyethyl)-rutoside-mediated protection of renal injury associated with cis-diamminedichloroplatinum(II)/hyperthermia treatment. Cancer Res 48:2239-44
Wassermann, K; Newman, R A; McLaughlin, J D et al. (1988) A possible role for altered poly(adenosine diphosphoribose)-synthesis in the sensitivity of human head and neck squamous carcinoma cells to ionizing radiation. Biochem Biophys Res Commun 154:1041-6
Wassermann, K; Newman, R A; Davis, F M et al. (1988) Selective inhibition of human ribosomal gene transcription by the morpholinyl anthracyclines cyanomorpholinyl- and morpholinyldoxorubicin. Cancer Res 48:4101-6
Felder, T B; McLean, M A; Vestal, M L et al. (1987) Pharmacokinetics and metabolism of the antitumor drug amonafide (NSC-308847) in humans. Drug Metab Dispos 15:773-8
Andersson, B S; Beran, M; Bakic, M et al. (1987) In vitro toxicity and DNA cleaving capacity of benzisoquinolinedione (nafidimide;NSC 308847) in human leukemia. Cancer Res 47:1040-4

Showing the most recent 10 out of 13 publications